高级检索
    邬麟, 卢红莲. Tepotinib治疗MET 14外显子跳读突变非小细胞肺癌患者的疗效与安全性[J]. 循证医学, 2020, 20(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2020.05.004
    引用本文: 邬麟, 卢红莲. Tepotinib治疗MET 14外显子跳读突变非小细胞肺癌患者的疗效与安全性[J]. 循证医学, 2020, 20(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2020.05.004
    shu
    WU Lin, LU Hong-lian. Efficacy and Safety of Tepotinib in Non-Small-Cell Lung Cancer With MET Exon 14 Skipping Mutations[J]. Journal of Evidence-Based Medicine, 2020, 20(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2020.05.004
    Citation: WU Lin, LU Hong-lian. Efficacy and Safety of Tepotinib in Non-Small-Cell Lung Cancer With MET Exon 14 Skipping Mutations[J]. Journal of Evidence-Based Medicine, 2020, 20(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2020.05.004
    shu

    Tepotinib治疗MET 14外显子跳读突变非小细胞肺癌患者的疗效与安全性

    Efficacy and Safety of Tepotinib in Non-Small-Cell Lung Cancer With MET Exon 14 Skipping Mutations

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回